Indivior is the world leader in addiction treatment with over 20 years’ experience and a unique patient‐focused approach. Our endeavour is to understand the journey of individuals suffering with addiction.
We partner with healthcare professionals, the public, policymakers, and payers to ensure people suffering from addiction are treated just like any other patients suffering from a chronic, relapsing medical condition.
Camurus is a Swedish research-based pharmaceutical company committed to developing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products are conceived based on the proprietary lipid-based FluidCrystal® drug delivery technologies and an extensive research and development expertise.
Camurus Australia’s focus is on opioid dependence, with the aim of simplifying treatment and removing the burden and stigma for patients and their families.
If you wish to learn more about Camurus’ medications, please visit the Buvidal website
As a new biopharmaceutical company, AbbVie combines the expertise of a recognised pharmaceutical company with the focus and innovative spirit of a biotech. Through a targeted, patient-centric approach to research and development, AbbVie accelerates new scientific discoveries to address some of the most complex diseases in the world, while our services and partnerships help us create greater access and outcomes for the health of all Australians. We focus on discovering, developing, and delivering medicines in therapeutic areas where we have proven expertise and where we can have an impact. These areas include: Immunology, Oncology, Virology and Neuroscience
ToxLogic offers client-specific drug and alcohol testing.
Our testing options include:
- drugs, alcohol and steroids in hair,
- drugs, alcohol and steroids in nails and
- PEth testing for alcohol via dried blood spot.
We advise clients on the most cost-effective choice for their circumstances and provide full support from sample collection to result interpretation.